COVID-19对肝脏及慢性肝病、肝胆肿瘤和肝移植患者诊疗的影响:EASL立场声明更新
欧洲肝脏研究学会(EASL)发布立场声明更新,总结COVID-19对肝脏影响的最新数据,并就慢性肝病、肝胆肿瘤及既往肝移植患者的诊疗提供指导。声明指出疫苗与治疗快速进展改善了临床局面,但奥密克戎变异株带来新挑战。
要点
- EASL发布立场声明更新,总结COVID-19对肝脏影响的最新数据。
- 声明针对慢性肝病、肝胆肿瘤及既往肝移植患者提供诊疗指导。
- 疫苗与治疗进展改善临床局面,奥密克戎变异株带来新挑战。
核心结论
- EASL发布立场声明更新,总结COVID-19对肝脏影响的最新数据,并就慢性肝病、肝胆肿瘤及既往肝移植患者的诊疗提供指导。
研究设计与样本
- 欧洲肝脏研究学会(EASL)制定的立场声明更新。
主要发现
- 疫苗与治疗的快速进展改善了临床局面,但奥密克戎变异株的出现带来新挑战。
临床怎么用
- 声明就慢性肝病、肝胆肿瘤及既往肝移植患者的诊疗提供指导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.
引用
- Marjot T, Eberhardt CS, Boettler T, et al. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. 2022. PMID: 35868584. doi:10.1016/j.jhep.2022.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。